Johnson & Johnson reports topline outcomes from trial of icotrokinra for psoriasis

Johnson & Johnson (J&J) has reported positive topline outcomes from its Phase III ICONIC-LEAD trial of oral icotrokinra (JNJ-2113) for treating moderate to severe plaque psoriasis in patients aged 12 years and older.